 Lexaria Bioscience Corp NASDAQ:LEXX CSE:LXX OTCMKTS:LXR announced Tuesday extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development RD program. Its been a very productive start into 2021 with a total of seven studies across our various research programs currently underway, said Lexaria CEO Chris Bunka in a statement. 